What Insulet's Quarter ended Sep 30, 2026 10-Q says: 7 signals
Insulet filed its latest 10-Q with the SEC on Nov 4, 2026. It discusses capex increase, cloud investment and international growth.
Public (PODD)Medical Equipment Manufacturing10,000+ employeesinsulet.comLinkedIn
Get Insulet's live signals in Claude or ChatGPT, or by API
What changed at Insulet this week? Use Autobound signals for insulet.com.- Filed
- Nov 4, 2026
- Period
- Quarter ended Sep 30, 2026
- Filings
- 3
- Signals
- 23
Source: Autobound Signal API · 102 signals tracked for Insulet · updated
10-Q · latest 10
What Insulet's 10-Q filings say
- SEC EDGAR
10-Q · Quarter ended Sep 30, 2026
Filed · 7 signals
Insulet incurred $38.5M charge and expects $50M total cost from cannula manufacturing issues
Insulet issued two voluntary medical device corrections in March and May 2026 related to separate manufacturing issues causing tears in product cannulas, recording a net charge of $38.5 million.
$50M
estimated total costs associated with the voluntary MDCs
Capital expenditures reached $113.9 million for the nine months ended September 30, 2026, up $57.5 million from $56.5 million in the prior year, primarily to purchase machinery, equipment, and tooling and invest in a new Costa Rica manufacturing plant.
$113.9M
Capital expenditures for the nine months ended September 30, 2026
International Omnipod revenue increased 31.7% to $266.2 million in Q3 2026
Revenue from Omnipod products in international markets rose 31.7% to $266.2 million for the quarter, or 33.0% on a constant currency basis, driven by customer base growth and higher average selling prices from Omnipod 5.
$266.2M
International Omnipod product revenue for Q3 2026
31.7%
International Omnipod revenue growth rate
Launched Omnipod Discover platform in U.S. in October 2026 after international rollouts
Insulet launched its web-based data platform Omnipod Discover in the United States in October, following earlier launches in five Middle East countries and Spain.
web-based data platform
Expanded Omnipod 5 and Omnipod Discover into Spain in July 2026
Insulet entered Spain in July 2026 with the launch of Omnipod 5 and Omnipod Discover, while also expanding integration with Libre 3 Plus to 10 additional countries.
Insulet invested $13.1M in developed software projects supporting cloud-based capabilities
Insulet directed $13.1 million into developed software projects during the nine months ended September 30, 2026, primarily to support cloud-based capabilities.
$13.1M
investments in developed software primarily related to projects supporting cloud-based capabilities
cloud
- SEC EDGAR
10-Q · Quarter ended Jun 30, 2026
Filed · 8 signals
Capital expenditures reached $56.8 million for the six months ended June 30, 2026, up from $30.9 million in the prior year period, primarily for machinery, equipment, tooling, and an initial investment in a Costa Rica manufacturing plant.
$56.8M
capital expenditures for the six months ended June 30, 2026
Insulet issues two voluntary medical device corrections with estimated costs of $60M-$70M
Insulet issued two voluntary medical device corrections in March and May 2026 regarding cannula tears in certain Omnipod products, recording charges of $41.0 million through June 30, 2026.
$70M
upper bound of estimated costs for voluntary medical device corrections
Insulet launches Omnipod 5 and Omnipod Discover in Middle East and Spain in 2026
Insulet launched Omnipod 5 and Omnipod Discover in five Middle Eastern countries in February 2026, followed by a launch in Spain in July 2026.
International Omnipod revenue grew 35.5% to $251.8 million for Q2 2026
International sales grew 35.5% (32.9% in constant currency) to $251.8 million in the three months ended June 30, 2026, driven by customer base growth and Omnipod 5 conversions.
$251.8M
International Omnipod product revenue for Q2 2026
35.5%
increase in international Omnipod product revenue for Q2 2026
Earlier 10-Q filings
- 10-Q · Quarter ended Mar 31, 2026Filed · 8 signalsSEC EDGAR
Showing 10 of 23 filing signals. The Signal API returns all of them.
Get them with one API callEarnings calls
Insulet earnings headlines
From earnings call transcripts (Signal API type earnings-transcripts).
| Call date | What the company said |
|---|---|
| Revenue reached $842M up 19.2% with operating margin at 22%Third-quarter revenue reached $842 million, representing 19.2% reported growth and 19.6% constant currency growth. Gross margin reached 74.2% while adjusted operating margin expanded 490 basis points to 22.0%, showing strong operational leverage and budget flexibility. | |
| Raised full year constant currency revenue growth outlook to 21%-22%Insulet narrowed its full-year revenue outlook to the high end of the prior range, anticipating 21% to 22% constant currency growth company-wide and 21.5% to 22.5% for total Omnipod. Adjusted operating margin expansion was lifted to approximately 150 basis points for full year 2026. | |
| Expanded domestic sales force by nearly 25% in Q3Insulet executed its second US commercial sales force expansion in two years, increasing field capacity by nearly 25%. The expansion included a four-month certification program and additions of clinical retention specialists to the customer care team. | |
| Full market release of Omnipod Discover completed in USInsulet launched Omnipod Discover across the US in October, scaling its proprietary engagement and decision-support platform. The release has already onboarded over 35,000 users and 5,000 clinicians to improve therapy retention and engagement. | |
| Deployed first new commercial CRM platform in over a decadeInsulet rolled out a new CRM platform to its US sales team in August to modernize customer engagement, messaging, and account targeting. Ongoing optimization and field training initiatives are underway to leverage the new platform's capabilities across commercial workflows. | |
| Global customer base grew over 20% past 600000 usersInsulet expanded its global active customer base by more than 20% year over year, building on the 600,000 baseline set at the end of last year. New customer starts grew low double digits year to date with more than 85% of starts converted from multiple daily injections. |
Signal API · MCP
Track Insulet with the Signal API
One POST /v1/companies/enrich call with insulet.com returns Insulet 10-Q signals (sec-10q), each with its source. Or ask Claude through MCP.
2 credits per signal returned; zero-result calls are free. Endpoint reference
curl -X POST https://signals.autobound.ai/v1/companies/enrich \
-H "X-API-KEY: $AUTOBOUND_API_KEY" \
-H "Content-Type: application/json" \
-d '{"domain":"insulet.com","signal_types":["sec-10q"],"limit":20}'Bulk data
Need this signal for 10,000+ companies?
Get a free sample file or a bulk feed (API, GCS push, flat file). The sample is real 10-Q Filings records, as a CSV.
Same industry
10-Q at related companies
Questions about Insulet 10-Q
When did Insulet file its latest 10-Q?
What did Insulet disclose in its latest 10-Q?
What did Insulet say on its recent earnings calls?
Where can I read Insulet's 10-Q filing?
Page updated , the date of the newest row on this page.
Source. Quarterly reports (Form 10-Q) filed with the SEC. Every card links to the filing on EDGAR.
Method. Insights are extracted from the filing text and grouped by category. Numbers are quoted from the filing.
Data as of .